/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Kura Oncology Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$11.79 0.0755(7.55%) KURA at 04 Dec 2025 04:36 PM Biotechnology
Lowest Today 11.31
Highest Today 12.1
Today’s Open 11.4
Prev. Close 11.13
52 Week High 12.49
52 Week Low 5.41
Day’s Range: Low 11.31 High 12.1
52-Week Range: Low 5.41 High 12.49
1 day return -
1 Week return -1.56
1 month return +20.14
3 month return +47.1
6 month return +84.85
1 year return +9.12
3 year return -24.44
5 year return -67.5
10 year return -

Institutional Holdings

BlackRock Inc 10.91

Suvretta Capital Management, LLC 9.35

Bvf Inc 8.93

Armistice Capital, LLC 7.14

Vanguard Group Inc 6.16

EcoR1 Capital, LLC 4.84

Prosight Management, LP 3.67

State Street Corp 3.50

Vanguard Total Stock Mkt Idx Inv 3.10

Millennium Management LLC 3.02

Geode Capital Management, LLC 2.32

Morgan Stanley - Brokerage Accounts 2.29

Qube Research & Technologies 2.20

iShares Russell 2000 ETF 2.17

SPDR® S&P Biotech ETF 1.48

Dimensional Fund Advisors, Inc. 1.43

HBM Healthcare Investments AG Ord 1.39

Jacobs Levy Equity Management, Inc. 1.27

Algert Global LLC 1.23

Renaissance Technologies Corp 1.22

Vanguard Institutional Extnd Mkt Idx Tr 1.12

Alethea Capital Management, LLC 1.09

AQR Capital Management LLC 1.08

Goldman Sachs Group Inc 1.08

Assenagon Asset Management SA 1.06

Invesco MSCI World ETF 1.03

Fidelity Small Cap Index 0.91

BlackRock Advantage Small Cap Core Instl 0.89

iShares Russell 2000 Value ETF 0.81

iShares Biotechnology ETF 0.57

Fidelity Extended Market Index 0.54

Schwab US Small-Cap ETF™ 0.47

Vanguard Russell 2000 ETF 0.44

Avantis US Small Cap Value ETF 0.42

DFA US Micro Cap I 0.33

State St Russell Sm Cap® Indx SL Cl I 0.30

Franklin US Small Cap Growth Equity 0.30

Rhenman Healthcare Equity L/S RC2 SEK 0.29

CREF Stock R3 0.29

Vanguard Explorer Inv 0.28

Market Status

Strong Buy: 10

Buy: 3

Hold: 2

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 968.51 M

PB Ratio 4.3555

PE Ratio 0.0

Enterprise Value 526.19 M

Total Assets 760.16 M

Volume 1454973

Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-142959000 -143.0M, FY22:-136069000 -136.1M, FY21:-129908000 -129.9M, FY20:-89431000 -89.4M, FY19:-63140000 -63.1M

Quarterly Revenue Q3/2025:20750000 20.8M, Q2/2025:15288000 15.3M, Q1/2025:14108000 14.1M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:17538000 17.5M, Q2/2025:15288000 15.3M, Q1/2025:14108000 14.1M, Q3/2024:null 0.0M, Q2/2024:-202000 -0.2M

Quarterly Net worth Q3/2025:-74116000 -74.1M, Q2/2025:-66122000 -66.1M, Q1/2025:-57429000 -57.4M, Q3/2024:-54404000 -54.4M, Q2/2024:-50837000 -50.8M

Fund house & investment objective

Company Information Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its lead product candidate includes ziftomenib, a selective investigational inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a selective investigational FTI for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies; and a clinical collaboration with Mirati Therapeutics, Inc. to evaluate the combination of KO-2806 and adagrasib, a KRASG12C inhibitor in patients with NSCLC. The company is headquartered in San Diego, California.

Organisation Biotechnology

Employees 192

Industry Biotechnology

CEO Dr. Troy Edward Wilson J.D., Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow